PEBP1 and neoplasm: Conversely, tumors derived from PC9 RKIP KO cells showed less responsiveness to treatment with 15 mg·kg−1 of Afatinib, as evidenced by the absence of tumor shrinkage over time compared to treated PC9 CTR tumors (Fig. 5H).